People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
WOOD Grand Rapids on MSN2d
Nose spray to treat depression? FDA approves first-of-its-kind medicineThe U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
There was no effect of insulin in the larger cohort using the second device. In a subsequent Phase 2 study to determine how much insulin entered the brain after nasal delivery, 19 people received 40 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback